Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Adma Biologics (ADMA) Return on Sales (2016 - 2025)

Historic Return on Sales for Adma Biologics (ADMA) over the last 14 years, with Q3 2025 value amounting to 0.27%.

  • Adma Biologics' Return on Sales fell 300.0% to 0.27% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.43%, marking a year-over-year increase of 2500.0%. This contributed to the annual value of 0.46% for FY2024, which is 5700.0% up from last year.
  • According to the latest figures from Q3 2025, Adma Biologics' Return on Sales is 0.27%, which was down 300.0% from 0.28% recorded in Q2 2025.
  • Adma Biologics' 5-year Return on Sales high stood at 0.95% for Q4 2024, and its period low was 1.14% during Q1 2021.
  • Moreover, its 5-year median value for Return on Sales was 0.12% (2023), whereas its average is 0.14%.
  • As far as peak fluctuations go, Adma Biologics' Return on Sales skyrocketed by 15300bps in 2021, and later crashed by -300bps in 2025.
  • Over the past 5 years, Adma Biologics' Return on Sales (Quarter) stood at 0.3% in 2021, then grew by 21bps to 0.24% in 2022, then dropped by -1bps to 0.24% in 2023, then surged by 499bps to 0.95% in 2024, then plummeted by -71bps to 0.27% in 2025.
  • Its Return on Sales was 0.27% in Q3 2025, compared to 0.28% in Q2 2025 and 0.23% in Q1 2025.